COMP <GO>
BLRX vs GDTC // ALTMAN Z-SCORE & DEBT/EQUITY
BioLineRx Ltd. (NASDAQ) VS. CytoMed Therapeutics Limited (NASDAQ) • 15-METRIC TALLY: BLRX 0
— GDTC 2
■ METRIC PARITY
LAST: $2.02 (+1.00%) • MKT CAP: $10.1M
balance-sheet
—
LAST: $0.90 (-3.68%) • MKT CAP: $10.7M
balance-sheet
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BLRX VS. GDTC)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BLRX | GDTC | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 35.3 | 51.9 | -16.65 | GDTC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.1M | $10.7M | -$596.7K | GDTC | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BLRX REV | GDTC REV | BLRX GROSS % | GDTC GROSS % | BLRX FCF | GDTC FCF |
|---|---|---|---|---|---|---|
| INSPECT INDIVIDUAL XBRL MODELS AT BLRX FA <GO> AND GDTC FA <GO>. | ||||||
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BLRX // BETA —
GDTC // BETA —